TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35176678
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) once weekly
Study: 35176678
Drug: Interpersonal Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Psychotherapy (IPT) twice weekly
Study: 35176678
Drug: Interpersonal Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Psychotherapy (IPT) once weekly
Study: 36448389
Drug: PVRU of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRU of 200 ml
Study: 36448389
Drug: PVRU of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRU of 300 ml
Study: 33727268
Drug: Local consolidation
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local consolidation radiation therapy (RT) and standard maintenance therapy
Study: 32761610
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted magnesium concentration (1 SD higher, SD: 0.08 mmol/L)
Study: 32761610
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted phosphorus concentration (1 SD higher, SD: 0.5 mg/dL)
Study: 36228641
Drug: Colchicine 1·2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1·2 mg followed by 0·6 mg 2 h later and then 0·6 mg twice daily for 28 days
Study: 36228641
Drug: Rivaroxaban 2·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2·5 mg twice daily plus aspirin 100 mg once daily for 28 days
Study: 36228641
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual care) for rivaroxaban and aspirin
Study: 34118178
Drug: Mobocertinib (TAK-788)
Normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobocertinib (TAK-788) 20-160 mg
Study: 34118178
Drug: Mobocertinib (120/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobocertinib (120/160 mg) under fasted or low-fat meal conditions
Study: 34118178
Drug: Mobocertinib 160
Normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobocertinib 160 mg in 1 of 2 capsule products
Study: 32151367
Drug: Naldemedine 0.2
Normalized name: naldemedine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine 0.2 mg once daily for 2 weeks (COMPOSE-4)
Study: 32151367
Drug: Naldemedine 0.2
Normalized name: naldemedine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine 0.2 mg once daily for 12 weeks (COMPOSE-5)
Study: 34508607
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily for 150 days)
Study: 35421407
Drug: Dentapen (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentapen (1.8 mL/162 sec, ramp-up setting)
Study: 35421407
Drug: Traditional syringe
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional syringe (1.8 mL/60 sec)
Study: 32847902
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual from EIP services (TAU)
Study: 32402523
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (control)
Study: 36413125
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray after an overnight fast
Study: 36413125
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray after a standardized high-fat, high-calorie breakfast
Study: 34125734
Drug: Average treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average treatment effect (ATE) with no assumptions
Study: 34125734
Drug: Average treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average treatment effect (ATE) with minimum assumptions
Study: 34125734
Drug: Complier average
Normalized name: Complera
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Complier average treatment effect (complier ATE)
Study: 33387498
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative body radiotherapy (SABR) with prescribed doses ranging from 24–60 Gy administered in three to eight fractions.
Study: 33539760
Drug: HIV clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV clinic-based buprenorphine plus naloxone treatment
Study: 35050355
Drug: Urolithin A
Normalized name: Urolithin A
DrugBank: Urolithin A (DB15464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urolithin A (1000 mg daily for 4 months)
Study: 32928313
Drug: 0.2% Povidone-Iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Povidone-Iodine gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Study: 32928313
Drug: 1% Hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Hydrogen peroxide gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Study: 32928313
Drug: Neem extract
Normalized name: neem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neem extract (Azardirachta indica) gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Study: 32928313
Drug: 2% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% hypertonic saline gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Study: 32928313
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water gargle and nasal lavage, 10 ml, for 20-30 seconds, thrice daily for 6 days
Study: 36167636
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg twice daily) plus sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Study: 36167636
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Study: 33315105
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nilotinib
Study: 33315105
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nilotinib
Study: 35072420
Drug: Coverage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coverage of all buccal cusps (T2)
Study: 35664443
Drug: Meningococcal conjugate
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal conjugate vaccine
Study: 35796800
Drug: Potassium oxalate
Normalized name: POTASSIUM OXALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium oxalate (Oxa-Gel BF)
Study: 35796800
Drug: Potassium oxalate
Normalized name: POTASSIUM OXALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium oxalate (Oxa-Gel BF) associated with low-power laser irradiation (POLL)
Study: 35166158
Drug: Psilocybin-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin-assisted treatment with supportive psychotherapy
Study: 35166158
Drug: Psilocybin-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin-assisted treatment
Study: 33770708
Drug: Extended interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended interval dosing (EID) regimen (MDI 6.1 weeks)
Study: 33770708
Drug: Standard interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interval dosing (SID) regimen (MDI 4.5 weeks)
Study: 32722731
Drug: Weekly yoga
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly yoga
Study: 33676296
Drug: Systemic lidocaine
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic lidocaine (1.5 mg kg−1 bolus, followed by 2 mg kg−1 h−1 infusion)
Study: 32770840
Drug: MgSO4 infusion
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 infusion (30 mg/kg loading dose followed by 10 mg/kg/hr continuous infusion)
Study: 32770840
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (same loading and maintenance infusion rates as MgSO4)
Study: 32490976
Drug: Baerveldt glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt glaucoma implant (250-mm2)
Study: 32757658
Drug: tPA dosing
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis (8 mg/2 hours, 8 mg/4 hours, 12 mg/6 hours, and 24 mg/6 hours)
Study: 32757658
Drug: tPA dosing
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis
Study: 32144974
Drug: Intra-articular oxygen-ozone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular oxygen-ozone therapy (O2O3)
Study: 35721497
Drug: Plasmalogen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalogen (2 mg per day)
Study: 32988373
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of fosaprepitant 150 mg
Study: 36806623
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg of 0.1% oestradiol gel per day
Study: 34323575
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment group (including weight losers and maintainers)
Study: 35433384
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of oral magnesium powder
Study: 33463492
Drug: Fat-modified enteral
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-modified enteral nutrition (EN) suspension
Study: 34872040
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% plus dexamethasone 8 mg
Study: 34176932
Drug: Intravenous landiolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous landiolol (started at 3 μg/min/kg dose and continued to a total of 50 mg; n=23)
Study: 34176932
Drug: Intravenous landiolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous landiolol (n=23)
Study: 35514746
Drug: Povidone-iodine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 0.5% and glycyrrhizic acid 2.5 mg/ml
Study: 35844134
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brivaracetam (BRV) monotherapy
Study: 35015856
Drug: standard micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard micronutrient powder (MNP) containing 4.1 mg zinc and 10 mg iron, daily
Study: 35015856
Drug: high-zinc (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-zinc (10 mg), low-iron (6 mg) (HiZn LoFe) MNP, daily
Study: 35015856
Drug: HiZn (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiZn (10 mg) LoFe (6 mg)/HiZn (10 mg), no-iron MNPs on alternating days
Study: 35015856
Drug: dispersible zinc
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dispersible zinc tablet (10 mg), daily
Study: 35015856
Drug: dispersible zinc
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dispersible zinc tablet (10 mg), daily for 2 wk at enrollment and 12 wk
Study: 35015856
Drug: placebo powder,
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo powder, daily
Study: 33310174
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g leucine
Study: 33310174
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g isoleucine
Study: 33876547
Drug: Smartphone-controlled patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-controlled patch electro-acupuncture (SCEA)
Study: 35123694
Drug: Standard-of-care (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (intravenous paclitaxel, pegylated liposomal doxorubicin, topotecan, oral letrozole, or oral tamoxifen)
Study: 34559801
Drug: Azithromycin (20mg/kg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20mg/kg, biannual single-dose)
Study: 34491646
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (oxiracetam capsules, 2 capsules, 3 times a day)
Study: 36330567
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug use (sertraline, fluvoxamine, risperidone, fluoxetine)
Study: 33634319
Drug: Low-iron MNP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron MNP (5 mg iron)
Study: 35179586
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) with capecitabine (850 or 1000 mg/m2) and bevacizumab (7.5 mg/kg)
Study: 35179586
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with capecitabine (850 or 1000 mg/m2) and bevacizumab (7.5 mg/kg)
Study: 35179586
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) with capecitabine and bevacizumab
Study: 34949156
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with systematic client feedback (SCF) based on the Partners for Change Outcome Management System (PCOMS)
Study: 35724857
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (3 mg/kg/day)
Study: 35724857
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (10 mg/kg/day)
Study: 32650818
Drug: Hydroxychloroquine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (600 mg first dose, then 200 mg twice daily for 7 days, total 3 g)
Study: 32650818
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent number of capsules to Hydroxychloroquine)
Study: 35881180
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment with sorafenib (either alone or combined with locoregional therapies)
Study: 33789555
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01, Bifidobacterium longum 04)
Study: 33789555
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (maltodextrin)
Study: 32506922
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (electronic medication tray and mHealth app)
Study: 36163020
Drug: Camostat mesilate
Normalized name: Camostat mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesilate (600 mg qid for up to 14 days)
Study: 33611132
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) or Relaxation Training (RT)
Study: 33479721
Drug: 80-mg ixekizumab
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg ixekizumab (IXE) every 2 weeks
Study: 33479721
Drug: 80-mg ixekizumab
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg ixekizumab (IXE) every 4 weeks
Study: 33479721
Drug: 80-mg ixekizumab
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg ixekizumab (IXE)
Study: 33602996
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 plus metformin
Study: 34240455
Drug: TAK-071 40-80
Normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-071 40-80 mg
Study: 34240455
Drug: TAK-071 120-160
Normalized name: TAK-071
DrugBank: TAK-071 (DB18954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-071 120-160 mg
Study: 34240455
Drug: TAK-071 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-071 (high doses)
Study: 33017484
Drug: Daily plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily plasma exchange and oral prednisone
Study: 32990214
Drug: HUG116 tablet;
Approvals — FDA: no, EMA: no, PMDA: no
Description: HUG116 tablet; tenofovir disoproxil
Study: 32990214
Drug: Viread tablet;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viread tablet; tenofovir disoproxil fumarate
Study: 36057498
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous fluid (37°C)
Study: 39415923
Drug: Pirtobrutinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib monotherapy
Study: 36164121
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of covalent BTK inhibitor monotherapy (ibrutinib, acalabrutinib, or zanubrutinib)
Study: 37755683
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise program including supervised walking, squat, balance, and inspiratory muscle training (IMT) with two daily sessions.
Study: 32053067
Drug: Various pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Various pharmaceutical agents (gonadotropins, anti‐estrogen agents, aromatase inhibitors)
Study: 34265312
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg/kg po QID)
Study: 39053954
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent dose)
Study: 32593228
Drug: E-learning on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-learning on smartphones with interactive learning materials including videos of dental treatments
Study: 33908131
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration in humans
Study: 33908131
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration in Ghsr knockout and wild-type rats
Study: 33908131
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration versus calorically equivalent non-alcoholic sucrose solution in rats
Study: 33908131
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration on ghrelin secretion from gastric mucosa cells ex vivo
Study: 35932720
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (10 UI once a day for 7 days)
Study: 35932720
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control group, once a day for 7 days)
Study: 32643076
Drug: No antibiotics/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics/placebo
Study: 35211743
Drug: Roluperidone 64
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roluperidone 64 mg/day
Study: 35211743
Drug: Roluperidone 32
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roluperidone 32 mg/day
Study: 35662406
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg bodyweight orally three times per week)
Study: 34697034
Drug: A. soehngenii
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. soehngenii infusion
Study: 37656449
Drug: Prophylactic ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prophylactic ranibizumab (PR) injections every 3 months
Study: 32306247
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 200 units/mL
Study: 32306247
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 units/mL
Study: 36074760
Drug: Tighter glycaemic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tighter glycaemic targets (FPG ≤5.0 mmol/L, 1-hour ≤7.4 mmol/L, 2-hour postprandial ≤6.7 mmol/L)
Study: 36074760
Drug: Less tight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less tight glycaemic targets (FPG <5.5 mmol/L, 1-hour <8.0 mmol/L, 2-hour postprandial <7.0 mmol/L)
Study: 32699911
Drug: Flaxseed muffins
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed muffins (30 g total, consumed once in the morning)
Study: 32699911
Drug: Flaxseed muffins
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed muffins (10 g per muffin, consumed three times a day)
Study: 32699911
Drug: Control muffins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control muffins (0 g flaxseed, consumed three times a day)
Study: 33308907
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable toric contact lenses
Study: 33961006
Drug: Colchicine (0.5-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5-1.0 mg daily)
Study: 32594766
Drug: LDL-C target
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C target of <70 mg/dL
Study: 32594766
Drug: LDL-C target
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C target of 100±10 mg/dL
Study: 33774942
Drug: Topical ozonated
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozonated sunflower oil (950 peroxide value) applied daily for one week
Study: 33774942
Drug: Non-ozonated sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ozonated sunflower oil (control) applied daily for one week